The Form 4 filing was submitted on October 13, 2026, covering a trade on October 9. This report of an insider's stock activity lists Boulding Mark Elliott as executive vice president and chief legal officer at PTC Therapeutics (PTCT).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-09 |
| Date of Latest Transaction | 2026-10-09 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 192 |
| Price | $64.26 |
| Total Transaction Value | $12,337.92 |
| Insider | |
| Ticker Symbol | PTCT |
| Company | PTC THERAPEUTICS, INC. |
| Insider Name | Boulding Mark Elliott |
| Insider Title | EXEC. VP AND CLO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 105,272 |
| Position Size Change | 0.18% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 192 shares, reported under SEC transaction code S. The record lists one sale transaction.
What was the average price of the transaction?
The reported average price was $64.26 per share for the 192 shares sold.
How did this transaction affect the insider's holdings?
The insider sold 192 shares and reported owning 105,272 shares afterward. The sale represented 0.18% of the shares owned before the trade.
What's the total transaction value?
The total value of the sale was $12,337.92.
Are there any special circumstances around this transaction?
Yes. The available information identifies a Rule 10b5-1 reference. These trading plans set instructions in advance. The details do not confirm whether the reference covers this specific sale or explain the plan's terms.
A matching share count also points to a related code M exercise or conversion in the same filing. Code M can cover receiving shares by using a stock option or converting another security into shares. A stock option gives someone the right to buy shares.
Only the sale details are available here, and the filing footnote text is unavailable. The matching share count alone does not confirm the same dates, types of shares, or accounts. It also does not prove that the shares received were the ones sold.
For research purposes only; not investment advice.